Numerous studies have firmly established the regulatory role of inflammatory cytokines in cancer.[3, 37-39, 46, 47, 50, 52] Our group has recently reported the reduction in prostate size and suppression of inflammatory cytokines by GHRH antagonists in a rodent model of experimental benign prostatic hyperplasia (BPH).[53] We have also demonstrated similar effects of GHRH antagonists on in vivo cytokine gene expression by HCC1806 and MX-1 triple negative human breast cancer. Here, MX1 is linked to benign prostatic hyperplasia.